Prostate:前列腺癌早期检测新荧光探针研究

2019-08-10 AlexYang MedSci原创

前列腺癌的早期检测能够明显的优化预后、延长患者寿命,并能够提高生活质量。已经有研究阐释了由于锌累积机制的损伤,前列腺癌组织具有比正常前列腺组织更低的锌含量。最近,有研究人员准备了一种新的基于吡咯并吡咯二酮(DPP)的荧光锌离子探针DPP-C2,且该新分子的荧光强度与环境锌离子的浓度成直接的比例关系。之后,研究人员在恶性肿瘤细胞(DU145和PC3细胞系)和正常前列腺RWPE-1细胞中进行了测试。研

前列腺癌的早期检测能够明显的优化预后、延长患者寿命,并能够提高生活质量。已经有研究阐释了由于锌累积机制的损伤,前列腺癌组织具有比正常前列腺组织更低的锌含量。

最近,有研究人员准备了一种新的基于吡咯并吡咯二酮(DPP)的荧光锌离子探针DPP-C2,且该新分子的荧光强度与环境锌离子的浓度成直接的比例关系。之后,研究人员在恶性肿瘤细胞(DU145和PC3细胞系)和正常前列腺RWPE-1细胞中进行了测试。研究发现,该探针对恶性和正常前列腺细胞表现出了很小的细胞毒性。RWPE-1细胞不仅表现出了很强的基线荧光,而且在补充锌离子的培养基中表现出了显著的荧光强度增强。在人类前列腺区域,病理学确定的癌症组织表现出了比正常和良性前列腺增生更弱的荧光信号。在合适的刺激下,前列腺组织表现出了比肿瘤组织更强的荧光信号,而其他临近组织几乎没有荧光信号。

最后,研究人员指出,他们的锌离子荧光探针DPP-C2是低毒的,并在前列腺癌早期检测中具有应用前景。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1743940, encodeId=72621e439403d, content=<a href='/topic/show?id=8fcd566e89c' target=_blank style='color:#2F92EE;'>#探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56678, encryptionId=8fcd566e89c, topicName=探针)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f76635239744, createdName=lvygwyt2793, createdTime=Tue Dec 03 16:06:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707798, encodeId=77a11e077986d, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Thu Nov 28 20:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942251, encodeId=e14c194225140, content=<a href='/topic/show?id=95bb8e250c5' target=_blank style='color:#2F92EE;'>#荧光探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87250, encryptionId=95bb8e250c5, topicName=荧光探针)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Feb 21 19:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364515, encodeId=93cb1364515d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Aug 12 12:06:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602187, encodeId=abf5160218e79, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Aug 12 12:06:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040520, encodeId=64e51040520cf, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Aug 11 00:06:00 CST 2019, time=2019-08-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1743940, encodeId=72621e439403d, content=<a href='/topic/show?id=8fcd566e89c' target=_blank style='color:#2F92EE;'>#探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56678, encryptionId=8fcd566e89c, topicName=探针)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f76635239744, createdName=lvygwyt2793, createdTime=Tue Dec 03 16:06:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707798, encodeId=77a11e077986d, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Thu Nov 28 20:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942251, encodeId=e14c194225140, content=<a href='/topic/show?id=95bb8e250c5' target=_blank style='color:#2F92EE;'>#荧光探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87250, encryptionId=95bb8e250c5, topicName=荧光探针)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Feb 21 19:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364515, encodeId=93cb1364515d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Aug 12 12:06:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602187, encodeId=abf5160218e79, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Aug 12 12:06:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040520, encodeId=64e51040520cf, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Aug 11 00:06:00 CST 2019, time=2019-08-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1743940, encodeId=72621e439403d, content=<a href='/topic/show?id=8fcd566e89c' target=_blank style='color:#2F92EE;'>#探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56678, encryptionId=8fcd566e89c, topicName=探针)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f76635239744, createdName=lvygwyt2793, createdTime=Tue Dec 03 16:06:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707798, encodeId=77a11e077986d, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Thu Nov 28 20:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942251, encodeId=e14c194225140, content=<a href='/topic/show?id=95bb8e250c5' target=_blank style='color:#2F92EE;'>#荧光探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87250, encryptionId=95bb8e250c5, topicName=荧光探针)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Feb 21 19:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364515, encodeId=93cb1364515d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Aug 12 12:06:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602187, encodeId=abf5160218e79, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Aug 12 12:06:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040520, encodeId=64e51040520cf, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Aug 11 00:06:00 CST 2019, time=2019-08-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1743940, encodeId=72621e439403d, content=<a href='/topic/show?id=8fcd566e89c' target=_blank style='color:#2F92EE;'>#探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56678, encryptionId=8fcd566e89c, topicName=探针)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f76635239744, createdName=lvygwyt2793, createdTime=Tue Dec 03 16:06:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707798, encodeId=77a11e077986d, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Thu Nov 28 20:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942251, encodeId=e14c194225140, content=<a href='/topic/show?id=95bb8e250c5' target=_blank style='color:#2F92EE;'>#荧光探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87250, encryptionId=95bb8e250c5, topicName=荧光探针)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Feb 21 19:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364515, encodeId=93cb1364515d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Aug 12 12:06:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602187, encodeId=abf5160218e79, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Aug 12 12:06:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040520, encodeId=64e51040520cf, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Aug 11 00:06:00 CST 2019, time=2019-08-11, status=1, ipAttribution=)]
    2019-08-12 医者仁心
  5. [GetPortalCommentsPageByObjectIdResponse(id=1743940, encodeId=72621e439403d, content=<a href='/topic/show?id=8fcd566e89c' target=_blank style='color:#2F92EE;'>#探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56678, encryptionId=8fcd566e89c, topicName=探针)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f76635239744, createdName=lvygwyt2793, createdTime=Tue Dec 03 16:06:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707798, encodeId=77a11e077986d, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Thu Nov 28 20:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942251, encodeId=e14c194225140, content=<a href='/topic/show?id=95bb8e250c5' target=_blank style='color:#2F92EE;'>#荧光探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87250, encryptionId=95bb8e250c5, topicName=荧光探针)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Feb 21 19:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364515, encodeId=93cb1364515d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Aug 12 12:06:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602187, encodeId=abf5160218e79, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Aug 12 12:06:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040520, encodeId=64e51040520cf, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Aug 11 00:06:00 CST 2019, time=2019-08-11, status=1, ipAttribution=)]
    2019-08-12 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1743940, encodeId=72621e439403d, content=<a href='/topic/show?id=8fcd566e89c' target=_blank style='color:#2F92EE;'>#探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56678, encryptionId=8fcd566e89c, topicName=探针)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f76635239744, createdName=lvygwyt2793, createdTime=Tue Dec 03 16:06:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707798, encodeId=77a11e077986d, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Thu Nov 28 20:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942251, encodeId=e14c194225140, content=<a href='/topic/show?id=95bb8e250c5' target=_blank style='color:#2F92EE;'>#荧光探针#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87250, encryptionId=95bb8e250c5, topicName=荧光探针)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Feb 21 19:06:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364515, encodeId=93cb1364515d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Aug 12 12:06:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602187, encodeId=abf5160218e79, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Aug 12 12:06:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040520, encodeId=64e51040520cf, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Aug 11 00:06:00 CST 2019, time=2019-08-11, status=1, ipAttribution=)]
    2019-08-11 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Sci Rep:环状RNAs在前列腺癌中差异化表达并与恩杂鲁胺抗性相关

大多数去势难治性前列腺癌(CRPC)的生存依赖于雄激素受体(AR)。然而,恩杂鲁胺虽然能够提供很大的生存益处,但是并不能治愈且许多患者产生治疗抗性。尽管抗性机制仍旧不清楚,但潜在的机制有很多,比如AR拷贝数变化和剪接本变异。环状RNAs(circRNAs)是一种新类型的非编码RNA,能够调控miRNA的功能,并且在药物抗性中可能具有重要的作用。circRNAs高度抗降解,并在血浆中可以检测到,因此

Lancet:超低分割放疗用于中高风险前列腺癌

研究发现,对于中高风险前列腺癌患者,超低分割放射治疗与常规分割放射治疗的效果无显著差异,虽然早期副作用更为明显,但晚期毒副作用相似

Mol Cancer Ther:AKR1C3能够促进AR-V7蛋白的稳定和产生AR靶向治疗抗性

导致去势抵抗性前列腺癌中的下一代雄激素抗性的机制仍旧不完全清楚。大量的研究确定了持续的雄激素受体(AR)信号或者全长AR旁路机制可能导致了抗性的产生。之前的研究阐释了AKR1C3和AR-V7在恩杂鲁胺和阿比特龙抗性中具有重要的作用。最近,有研究人员发现AKR1C3能够增加AR-V7在抗性前列腺癌细胞中的表达,具体机制是通过激活泛素调控的蛋白酶体途径来增强蛋白的稳定性。在恩杂鲁胺抗性前列腺癌细胞中,

机器人治疗前列腺癌!智慧医疗时代 泌尿外科“黑科技”有多牛?

科技创新是我国经济社会发展的重要战略。随着科技与医学的融合,新理念、新技术在泌尿外科领域得到了广泛应用和实践,如激光技术、机器人、“互联网+”、5G等等。为了更好地促进泌尿外科新技术的应用,医学基础走向转化,临床与科技相结合,以及互联网医疗赋能专科和基层。8月4日, 由国家远程医疗及互联网医学中心、中日友好医院泌尿外科、北京医学会泌尿外科分会基础与转化研究学组联合主办的“2019中日泌尿新技术高峰

Sci Rep:miR-424-3p的低水平表达与前列腺癌的临床失败高度相关

前列腺癌(PC)是一种高度异质性的疾病,并且是发达国家主要的致死性疾病之一。之前的研究表明了许多癌症中免疫检查点蛋白的表达直接或者间接的受microRNAs(miRs)的抑制。基于miRs的治疗方法的巨大优势是这些短的转录本具有靶向同一途径或者不同途径的多个分子的能力,具有系统免疫抑制的作用。之前有报道miR-24是不同类型癌症的不良预后生物标记。miR-424同时靶向CTLA-4/CD80-和P

阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功

阿斯利康和MSD宣布其联合开发药物Lynparza(olaparib)已达到III期前列腺癌临床试验的主要终点,在转移性去势抵抗性前列腺癌(mCRPC)的男性患者中,该药物显着增加了BRCA1 / 2或ATM突变的患者在没有放射照相疾病进展的情况下的生存时间。